Twist Bioscience (TWST) Jumps As Guidance, Offering Reset The Trade

Twist Bioscience Corporation stocks have been trading up by 16.14 percent after positive synthetic DNA demand and capacity expansion news

Live Update At 16:47:19 EDT: On Wednesday, August 05, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 16.14%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Twist Bioscience (TWST) has turned into a momentum name again. The stock ripped from a $81.60 area close on 2026/08/03 to $115.01 on 2026/08/05, a massive multi‑day squeeze after earnings and guidance. That is the kind of range active traders hunt.

On the tape, the 5‑minute chart shows TWST grinding higher intraday, holding above $110 for most of the session and closing near the highs. That tells you dip buyers controlled the day and shorts were on defense.

Fundamentally, TWST just printed Q3 revenue of $118.4M, up more than 23% year over year and above roughly $114.5M consensus. The flip side: the company is still losing money, with EPS at ($0.56) and EBITDA margin around -26%. Gross margin near 52% is a bright spot, showing the core DNA synthesis business throws off strong unit economics even while operating expenses stay heavy.

Key ratios show TWST as a classic high‑growth, not‑yet‑profitable story. Price‑to‑sales near 15 and negative returns on equity and assets underscore that traders are paying up for revenue growth and future cash flow, not current earnings. With a solid current ratio around 2.7 and modest leverage, bankruptcy risk looks low, but execution risk remains front and center.

Why Traders Are Watching TWST’s Momentum

The real reason TWST is back on every momentum screen is the forward outlook. Management didn’t just beat Q3; they raised the bar. Twist Bioscience now guides Q4 revenue to $123M–$124M, well ahead of the roughly $117M the Street had penciled in, and calls for adjusted EBITDA breakeven. For a story stock like TWST, that “breakeven” word matters. It’s a psychological line that often pulls in new funds and squeezes crowded shorts.

Looking further out, Twist Bioscience pushed FY26 revenue guidance up to $456M–$457M, versus a prior $442M–$447M and market expectations around $445M. They also see gross margin above 52%, signaling operating leverage should kick in as volume scales. Add management’s target for another year of triple‑digit growth in AI‑enabled drug discovery orders in FY27, and you get a clean secular growth pitch around synthetic DNA and AI drug discovery.

Analysts are reacting. TD Cowen took its TWST price target to $115 from $89 and reaffirmed a Buy call after the print, while Baird nudged its target to the same $115 with an Outperform view. One Cowen note coincided with TWST trading near $95.66 and jumping roughly 4.5% on the day, proof that this name still responds sharply to research headlines.

There is a catch. Twist Bioscience also swung to a larger‑than‑expected loss versus a profit a year ago, and the stock actually traded down about 6.3% pre‑market right after earnings. That tells you some traders were spooked by valuation and red ink, even as guidance marched higher. Then came the upsized $300M stock offering at $96. For short‑term players, that is textbook dilution and often caps upside near the deal price.

But the use of proceeds matters: funding R&D, manufacturing expansion, and new products gives Twist Bioscience more ammo to chase the AI and drug discovery wave. Combined with inducement RSUs for 24 new hires, the company is clearly in build‑out mode. Active traders in TWST now have a classic tug‑of‑war setup: strong growth and bullish analysts versus dilution, past losses, and a stretched chart after a vertical move.

Conclusion

For active traders, TWST is no sleepy biotech. It is a high‑beta vehicle tied to big themes: synthetic biology, AI‑driven drug discovery, and the broader shift toward data‑heavy R&D. The latest numbers show Twist Bioscience growing fast, raising guidance, and steering toward adjusted EBITDA breakeven as soon as Q4. At the same time, negative margins, a fresh $300M equity raise, and lofty sales multiples keep the risk side very real.

Short term, the chart says momentum. TWST broke out from the low‑$80s and closed around $115 on 2026/08/05, with intraday action holding higher lows all afternoon. That’s classic trend behavior. But parabolic moves rarely last forever. Traders who chase need tight risk controls and clear exit levels if Twist Bioscience snaps back toward the $96 offering zone or lower.

Longer term, everything comes down to execution. If Twist Bioscience delivers on that $456M–$457M FY26 revenue target, sustains gross margin north of 52%, and turns adjusted EBITDA breakeven into real profitability by fiscal 2027, the current valuation can look a lot more reasonable than it does today. If not, high‑multiple names like TWST tend to get punished hard.

As Tim Sykes loves to remind traders, “Trade the price action, not the hype — patterns and risk management always matter more than the story.” That focus on patterns, rules, and risk lines up with his broader philosophy on how to approach volatile names like TWST. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. TWST’s story is strong, but trading it still comes down to your plan, your discipline, and how you handle both sides of volatility. This analysis is for educational and research purposes only and is not advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks